Kiniksa Pharmaceuticals International (KNSA) Other Non-Current Assets (2017 - 2026)

Kiniksa Pharmaceuticals International's Other Non-Current Assets history runs 10 years deep, the most recent figure standing at $11.2 million for Q1 2026.

• Quarterly Other Non-Current Assets rose 36.09% year-over-year to $11.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.2 million (up 36.09% YoY) and the FY2025 annual result came in at $11.3 million, up 9.62% from the prior year.
• Other Non-Current Assets was $11.2 million for Q1 2026 at Kiniksa Pharmaceuticals International, down from $11.3 million in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $11.3 million in Q4 2025 and bottomed at $827000.0 in Q4 2023.
• A 5-year average of $6.4 million and a median of $5.9 million in 2022 frame the typical range for Other Non-Current Assets.
• Annual changes were most pronounced in 2023 — Other Non-Current Assets plunged 85.8% — and 2024, when it soared 1147.28%.
• Kiniksa Pharmaceuticals International's Other Non-Current Assets stood at $5.8 million in 2022, then plunged by 85.8% to $827000.0 in 2023, then surged by 1147.28% to $10.3 million in 2024, then rose by 9.62% to $11.3 million in 2025, then decreased by 1.28% to $11.2 million in 2026.
• Business Quant data shows KNSA's Other Non-Current Assets at $11.2 million in Q1 2026, $11.3 million in Q4 2025, and $8.3 million in Q3 2025.